Search Results - "Marinucci, Lawrence N"

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial by Goodman, Andrew D, Prof, Brown, Theodore R, MD, Krupp, Lauren B, MD, Schapiro, Randall T, MD, Schwid, Steven R, MD, Cohen, Ron, MD, Marinucci, Lawrence N, MS, Blight, Andrew R, PhD

“…Summary Background Clinical studies suggested that fampridine (4-aminopyridine) improves motor function in people with multiple sclerosis. This phase III study…”
Get full text

Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis by Coleman, Craig I., Sobieraj, Diana M., Marinucci, Lawrence N.

“…Abstract Background: Limited data define what constitutes a clinically significant change on the Timed 25-Foot Walk (T25FW) in multiple sclerosis (MS);…”
Get full text

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis by Goodman, Andrew D., Brown, Theodore R., Edwards, Keith R., Krupp, Lauren B., Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N., Blight, Andrew R.

“…Objective A previous phase 3 study showed significant improvement in walking ability in multiple sclerosis (MS) patients treated with oral, extended‐release…”
Get full text

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials by Goodman, Andrew D, Bethoux, Francois, Brown, Theodore R, Schapiro, Randall T, Cohen, Ron, Marinucci, Lawrence N, Henney, Herbert R, Blight, Andrew R, Agius, M, Arnason, BGW, Bethoux, FA, Bever, CT, Bowen, JD, Brown, TR, Dietrich, DW, Edwards, K, Freedman, MS, Freedman, M, Kachuck, NJ, Kaufman, MD, Keilson, M, Khan, O, Krupp, LB, Leist, TP, Lindsey, JW, Lublin, FD, Mass, MK, Mattson, D, McGowan, D, Naismith, R, O’Connell, C, Oger, JJ, Panitch, H, Picone, MA, Rammohan, KW, Schapiro, RT, Schwid, SR, Scott, T, Short, C, Thrower, BW, Vollmer, TL, Camac, A, Cooper, JA, Chumley, WF, Cross, A, Dunnigan, RT, Gitt, JS, Hillen, M, Jeffrey, DR, Khatri, BO, Kresa-Reahl, K, Moon, S, Preiningerova, J, Tullman, M, Weinstock-Guttman, B, Wynn, DR

“…Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release…”
Get full text

Effects of aging, diet, and sex on plasma glucose, fructosamine, and lipid concentrations in barrier-raised Fischer 344 rats by Van Liew, J B, Davis, P J, Davis, F B, Bernardis, L L, Deziel, M R, Marinucci, L N, Kumar, D

“…We studied the relationships of plasma glucose, fructosamine, triglycerides, and cholesterol as a function of age, gender, and diet in barrier-raised Fischer…”
Get more information